What the research found

This is an industry report rather than peer-reviewed research, but it documents several concrete observations about the peptide supply ecosystem. Independent testing of peptides purchased through AliExpress (marketed as glassware) returned results suggesting authentic compounds: retatrutide samples showed purities of 95–99% with quantities close to label claims, and a tirzepatide sample exceeded its label by approximately 9%. Meanwhile, pricing from one Chinese supplier fell roughly 26% over six months, though the report notes this is a single vendor and may not reflect broader market trends.

The more significant finding concerns variability in independent testing itself. When the same peptide products were analysed by different laboratories, results diverged substantially—one retatrutide sample showed purities ranging from 36% to 98%, depending on which lab performed the analysis. This inconsistency raises questions about lab methodology, calibration or reporting standards rather than product authenticity alone.

Why it matters for you

If you're sourcing peptides outside traditional pharmaceutical channels, this highlights two practical concerns. First, the testing labs you rely on to verify your compounds may not be directly comparable to each other—a "clean" report from Lab A might not mean the same thing as Lab B's result. You can't yet treat independent testing as a standardised quality benchmark. Second, even if you find authentic-appearing compounds at lower prices, the supply chain opacity is real: the seller you buy from may have little direct control over synthesis, filling or storage conditions, creating hidden risks around sterility, endotoxin levels and long-term stability that a single purity test won't capture.

For biomarker tracking and protocol adherence, this matters because an impure or mislabelled peptide introduces a major confounding variable. If your GLP-1 or tirzepatide isn't what you think it is, your metabolic response, appetite suppression and body composition changes become impossible to interpret reliably.

Caveats

  • Single-vendor price monitoring; cannot be generalised across the Chinese market
  • Very small sample size for AliExpress testing (n=3 across two compounds)
  • Laboratory discrepancies may reflect testing methodology differences rather than product quality alone; no reference standard or proficiency testing data provided
  • Observational/industry reporting rather than controlled research
  • No data on long-term stability, storage conditions or endotoxin profiles beyond one sample